Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: A retrospective claims database analysis

Clinical Therapeutics

Volumn 30, Issue 2, 2008, Pages 358-371

  Ye, Xin ^a   Sikirica, Vanja ^b   Schein, Jeffrey R ^b   Grant, Richard ^c   Zarotsky, Victoria ^a   Doshi, Dilesh ^b   Benson, Carmela Janagap ^b   Riedel, Aylin A ^a  

^a i3 Innovus   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CAP; claims analysis; community acquired pneumonia; costs; levofloxacin; macrolides; resource utilization; treatment failure

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BILLING AND CLAIMS; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFIDENCE INTERVAL; DATA BASE; DEMOGRAPHY; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; OUTPATIENT DEPARTMENT; PHYSICIAN; POST HOC ANALYSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; DATABASES AS TOPIC; DRUG COSTS; DRUG UTILIZATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITAL COSTS; HUMANS; INSURANCE CLAIM REPORTING; LOGISTIC MODELS; MACROLIDES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; ODDS RATIO; OFLOXACIN; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE;

EID: 41549095832     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.023     Document Type: Article

References (46)

1. Miniño A., Heron M., and Smith B. Deaths: Preliminary data for 2004 (2006), National Center for Health Statistics, Hyattsville, Md
2. Mandell L., Bartlett J., Dowell S., et al., Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37 (2003) 1405-1433
3. Niederman M., Mandell L., Anzueto A., et al., American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163 (2001) 1730-1754
4. DeFrances C., and Podgornik M. 2004 National Hospital Discharge Survey (2006), National Center for Health Statistics, Hyattsville, Md
5. Niederman M., McCombs J., Unger A., et al. The cost of treating community-acquired pneumonia. Clin Ther 20 (1998) 820-837
6. Colice G., Morley M., Asche C., and Birnbaum H. Treatment costs of community-acquired pneumonia in an employed population. Chest 125 (2004) 2140-2145
7. Mandell L., Marrie T., Grossman R., et al., Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31 (2000) 383-421
8. Segreti J., House H., and Siegel R. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 118 Suppl 7A (2005) 21S-28S
9. Dixon R. Economic costs of respiratory tract infections in the United States. Am J Med 78 Suppl 2 (1985) 45-51
10. Mandell L. Advances in antimicrobial therapy of community-acquired pneumonia. Curr Opin Infect Dis 12 (1999) 137-143
11. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 50 Suppl 1 (2004) 3-10
12. File Jr. T., and Tan J. International guidelines for the treatment of community-acquired pneumonia in adults: The role of macrolides. Drugs 63 (2003) 181-205
13. Reinert R., Hoban D., Felmingham D., and Pluim J. World surveillance of antibiotic resistance among clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes during 1999/2000. Abstr Intersci Conf Antimicrob Agents Chemother 41 (2001) Abstract C2-692
14. Klugman K., and Lonks J. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 11 (2005) 802-807
15. Meehan T., Fine M., Krumholz H., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278 (1997) 2080-2084
16. Gleason P., Meehan T., Fine J., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 159 (1999) 2562-2572
17. Houck P., Bratzler D., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164 (2004) 637-644
18. Bodi M., Rodríguez A., Solé-Violán J., et al., Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: Impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 41 (2005) 1709-1716
19. Academy for Infection Management. Education slide resource kit. February 2004. http://www.infectionacademy. org/downloads/AIM_educational_slide_resource_kit.ppt#371,1,Educational%20slide%20resource% 20kit Accessed July 23, 2007
20. Moran G. Approaches to treatment of community-acquired pneumonia in the Emergency Department and the appropriate role of fluoroquinolones. J Emerg Med 30 (2006) 377-387
21. Wang L., and Barrett J. Pharmacoeconomics of treatment with the newer anti-Gram-positive agents. Expert Opin Pharmacother 7 (2006) 885-897
22. Carmeli Y., Troillet N., Karchmer A., and Samore M. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 159 (1999) 1127-1132
23. Cosgrove S., Kaye K., Eliopoulous G., and Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 162 (2002) 185-190
24. Bjerre L., Verheij T., and Kochen M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2 (2004) CD002109
25. Heffelfinger J., Dowell S., Jorgensen J., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 160 (2000) 1399-1408
26. Mandell L., Wunderink R., Anzueto A., et al., Infectious Diseases Society of America and the American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
27. Dunbar L., Wunderink R., Habib M., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm [published correction appears in Clin Infect Dis. 2003;37:1147]. Clin Infect Dis 37 (2003) 752-760
28. Preston S., Drusano G., Berman A., et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 279 (1998) 125-129
29. O'Doherty B., Muller O., and Azithromycin Study Group. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 17 (1998) 828-833
30. Hoepelman I., Möllers M., van Schie M., et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxicillinclavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 9 (1997) 141-146
31. Fine M., Auble T., Yealy D., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 (1997) 243-250
32. Arnold F., LaJoie A., Marrie T., et al. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. Int J Tuberc Lung Dis 10 (2006) 739-743
33. Renaud B., Coma E., Labarere J., et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: A multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 44 (2007) 41-49
34. Charlson M., Pompei P., Ales K., and MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
35. Deyo R., Cherkin D., and Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
36. Red Book: Pharmacy's Fundamental Reference. 2007 Edition (2007), Thomson Healthcare Inc, Montvale, NJ
37. Samsa G., Matchar D., Harnett J., and Wilson J. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: Results from the CAP-IN trial. Chest 128 (2005) 3246-3254
38. Nathwani D. Cost and dosing issues. J Chemother 12 Suppl 1 (2001) 15-18
39. Wu J., Howard D., McGowan Jr. J., et al. Adherence to Infectious Diseases Society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort. Clin Ther 28 (2006) 1451-1461
40. Rajagopalan S., and Yoshikawa T. Antimicrobial therapy in the elderly. Med Clin North Am 85 (2001) 133-147
41. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-1999. MMWR Morb Mortal Wkly Rep 50 (2001) 800-804
42. MacDougall C., Guglielmo B., Maselli J., and Gonzales R. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis 11 (2005) 380-384
43. Waterer G., Buckingham S., Kessler L., et al. Decreasing β-lactam resistance in pneumococci from the Memphis region: Analysis of 2152 isolates from 1996 to 2001. Chest 124 (2003) 519-525
44. Chen D., McGeer A., de Azavedo J., Low D., and Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341 (1999) 233-239
45. Karlowsky J., Thornsberry C., Jones M., et al., TRUST Surveillance Program. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (19982002). Clin Infect Dis 36 (2003) 963-970
46. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network. Streptococcus pneumoniae, 2003. http://www.cdc.gov/ ncidod/DBMD/abcs/survreports/spneum03.pdf Accessed July 20, 2007